These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10513271)

  • 1. Unconventional therapies and cancer.
    Bégin M; Kaegi E
    CMAJ; 1999 Sep; 161(6):686-7. PubMed ID: 10513271
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Tuma RS
    J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologic and biologic therapies in cancer care: Part II.
    Decker GM
    Clin J Oncol Nurs; 2000; 4(6):283-4, 287. PubMed ID: 11899327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unconventional therapies for cancer: a refuge from the rules of evidence?
    Tannock IF; Warr DG
    CMAJ; 1998 Oct; 159(7):801-2. PubMed ID: 9805028
    [No Abstract]   [Full Text] [Related]  

  • 5. The challenges of randomized trials in integrative cancer care.
    Block KI; Cohen AJ; Dobs AS; Ornish D; Tripathy D
    Integr Cancer Ther; 2004 Jun; 3(2):112-27. PubMed ID: 15165498
    [No Abstract]   [Full Text] [Related]  

  • 6. Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.
    Kaegi E
    CMAJ; 1998 May; 158(10):1327-30. PubMed ID: 9614826
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecule of the month. Elesclomol and obatoclax mesylate.
    Drug News Perspect; 2008 Mar; 21(2):123-4. PubMed ID: 18389103
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamin C as a cancer treatment: state of the science and recommendations for research.
    Tamayo C; Richardson MA
    Altern Ther Health Med; 2003; 9(3):94-101. PubMed ID: 12776480
    [No Abstract]   [Full Text] [Related]  

  • 9. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 11. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 13. Multi-arm clinical trials of new agents: some design considerations.
    Freidlin B; Korn EL; Gray R; Martin A
    Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Di Bella multitherapy trial. Criticism ignores standard methodology of cancer treatments.
    Raschetti R; Greco D; Menniti-Ippolito F; Spila-Alegiani S; Benagiano G; Bruzzi P
    BMJ; 1999 Apr; 318(7190):1074. PubMed ID: 10336293
    [No Abstract]   [Full Text] [Related]  

  • 15. Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology.
    Efficace F; Horneber M; Lejeune S; Van Dam F; Leering S; Rottmann M; Aaronson NK
    J Clin Epidemiol; 2006 Dec; 59(12):1257-65. PubMed ID: 17098568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trials as evidence in legal disputes about the benefits of complementary and alternative medicine.
    Coulter ID; Walsh J
    Altern Ther Health Med; 2008; 14(2):60-4. PubMed ID: 18383991
    [No Abstract]   [Full Text] [Related]  

  • 17. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 18. Complementary and alternative therapies: the power of randomization.
    Wild R
    J Soc Gynecol Investig; 2006 Jan; 13(1):1. PubMed ID: 16378909
    [No Abstract]   [Full Text] [Related]  

  • 19. The roles of complementary medicine in oncology.
    Lamson DW
    Altern Med Rev; 2007 Dec; 12(4):313-8. PubMed ID: 18069900
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trials in journal of clinical oncology.
    Cannistra SA
    J Clin Oncol; 2009 Jul; 27(19):3073-6. PubMed ID: 19451415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.